Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2023-08-16 Report Publication Anno…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1240 characters) explicitly titled 'Invitation to second quarter 2023 results webcast presentation'. It states that the 'report and presentation will be available on the company website from 08:00 CET the same day' and invites users to a webcast presentation. This structure—announcing the availability of results/reports rather than containing the full results or the report itself—fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, but the notice about its release and associated presentation.
2023-08-16 English
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients
Regulatory Filings Classification · 100% confidence The document is a press release from Ultimovacs ASA announcing the completion of patient enrollment in a Phase II clinical trial (FOCUS study) for their drug UV1. It details the trial status, expected results timeline (H2 2024), and provides background on the disease, the drug, and the broader clinical program. This type of announcement, focusing on operational milestones (like enrollment completion) and future data release expectations, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational update that is not a full financial report (10-K, IR) or a formal regulatory filing like a Director's Dealing or Major Shareholding notification, and it is not merely announcing the publication of another report (RPA), it fits best as an Earnings Release (ER) as these often contain key operational and clinical milestones alongside financial highlights, or RNS as a general regulatory announcement. Given the focus on clinical trial progress and the date/time stamp suggesting a formal release, RNS is the most appropriate general category for non-standard, material operational news, although ER is also plausible if this was released alongside quarterly results. Since the text is substantial and contains detailed operational news rather than just financial highlights, and it is not a standard financial report, I will classify it as a Regulatory Filing (RNS) as it is a material, non-standard announcement. However, reviewing the definitions, 'ER' is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is primarily a clinical trial update, not a financial results highlight. Therefore, 'RNS' (General regulatory announcements and fallback category) is the most suitable classification for a material, non-financial, operational press release.
2023-08-03 English
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results
Investor Presentation Classification · 95% confidence The document is a press release titled "Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results". It details the publication of clinical trial results in a peer-reviewed journal and provides key data points, context about the trial, and company background. This structure—announcing the release/publication of detailed findings rather than being the full, formal regulatory report (like a 10-K or IR)—points towards an announcement about a report or data release. Since it is announcing the publication of scientific/clinical data, it is best classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were summarizing financial performance. However, the core action is announcing the publication of clinical trial results in a journal, which is a form of disseminating important company information to investors. Given the options, this is a high-level announcement of data dissemination. It is not a formal regulatory filing like 10-K or IR. It is more detailed than a typical ER, but it serves the function of informing investors about new data. Since it is announcing the publication of clinical trial results, which is a key piece of investor information, and it is not a generic regulatory filing (RNS), the closest fit among the specific categories that cover data dissemination is Investor Presentation (IP), as it contains detailed results and context often found in presentations, even though it's framed as a publication announcement. Alternatively, because it is an announcement about the publication of results, it could be considered a Report Publication Announcement (RPA), but RPA is usually for the company's own periodic reports (like 10-K or IR). Given the content is detailed clinical trial results being made public, IP is a strong fit for the *type* of information being shared, but the document itself is an announcement of that sharing. Since the document is long (9006 chars) and contains substantial data, it is not a simple RPA/RNS announcement wrapper. It functions as a detailed update. Given the focus on clinical trial results and data dissemination, IP is the most appropriate classification for the substance being communicated.
2023-06-28 English
Ultimovacs' Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award's Honorary Prize as an Outstanding Pioneer Against Cancer
Board/Management Information Classification · 99% confidence The document is explicitly labeled as a "NON-REGULATORY PRESS RELEASE" announcing that the Chief Scientific Officer, Gustav Gaudernack, received an Honorary Prize from the Norwegian Tech Award. This type of announcement, which details an award or recognition for a key executive, does not fit into the specific financial reporting categories like 10-K, ER, or IR. It is a general corporate announcement regarding personnel/management recognition. While it relates to management, it is not a change in the board/management structure (MANG) but rather an external award. Since it is a press release announcing a specific, non-financial event, and it doesn't fit the other specific categories, the most appropriate classification is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), as it is a public disclosure that doesn't fit the defined financial or governance reports.
2023-06-22 English
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine
Earnings Release Classification · 95% confidence The document is a press release from Ultimovacs ASA announcing 3-year overall survival data from a Phase I clinical study (UV1-103) regarding their cancer vaccine UV1 in malignant melanoma. It details clinical results (OS, ORR, mPFS), mentions ongoing Phase II trials (INITIUM), and concludes with standard company information and contact details. This type of announcement, focusing on clinical trial results and updates, is characteristic of an Earnings Release (ER) or a general Investor Relations update. Since it is a specific announcement of results rather than a comprehensive annual/interim report (10-K/IR) or a transcript (CT), ER is the most appropriate fit for disseminating key performance/study results. It is not a formal regulatory filing like a 10-K or a proxy statement. Given the content is focused on announcing key performance indicators (survival rates) from a study, ER is selected over the broader RNS. Q2 2023
2023-06-19 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document text is titled 'KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar («primærinnsider») og deres nærstående' (KRT-1500 Form for reporting transactions carried out by persons discharging managerial responsibilities ('primary insiders') and their related persons). It details a transaction (Kjøp/Buy) involving shares (Aksje) by an individual identified as a 'Boardmember' (Ketil Fjerdingen) and reports the price, volume, and date (08.06.2023). This structure is characteristic of mandatory insider trading disclosures, specifically reporting personal share transactions by directors and executives. This directly matches the definition for Director's Dealing (DIRS).
2023-06-08 Norwegian

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.